Q1 2025 Conmed Corp Earnings Call Transcript
Key Points
- Conmed Corp (CNMD) reported a year-over-year sales increase of 2.9% as reported and 3.8% in constant currency, slightly exceeding guidance.
- Adjusted net income increased by 19.6% year-over-year, with adjusted diluted net earnings per share rising by 20.1%.
- The company received FDA clearance for a new delivery device for BioBrace in rotator cuff repair, which is expected to enhance surgical procedures.
- Strong demand was noted for BioBrace, with double-digit sales growth in foot and ankle products and significant clinical adoption.
- Conmed Corp (CNMD) is making progress in supply chain initiatives, with a decline in the number of SKUs on backorder and expectations for further improvements by year-end.
- Supply chain challenges persist, particularly affecting the orthopedics segment in the U.S., where sales decreased by 2.1%.
- International general surgery sales declined by 3.3%, attributed to weaknesses in energy and critical care product lines.
- The company faces potential tariff impacts, with an estimated $5.5 million exposure in 2025, primarily from China.
- Adjusted gross margin improvements are expected to be delayed, with significant benefits not materializing until 2026.
- Despite a positive quarter, the company maintained its full-year revenue growth guidance at 4% to 6%, indicating caution amid macroeconomic uncertainties.
Good day, and thank you for standing by. Welcome to CONMED's first-quarter fiscal 2025 earnings conference call. (Operator Instructions)
Please be advised that today's conference is being recorded. Before the conference call begins, let me remind you that during this call, management will be making comments and statements regarding its financial outlook, its plans and objectives. These statements represent the forward-looking statements that involve risks and uncertainties as those terms are defined under the federal securities laws.
Investors are cautioned that any such forward-looking statements are not guarantees of future events, performance or results. The company's actual results may differ materially from its current expectations. Please refer to the risks and other uncertainties disclosed under the forward-looking information in today's press release, as well as the company's SEC filings, for more details on the risks and uncertainties that may cause actual results to differ materially. The company disclaims any obligation to update any forward-looking statements that may be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
